Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2021-08-24 Earnings Release
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Financial Results for a Period of Six Months Ending June 30, 2021
Earnings Release Classification · 99% confidence The document explicitly states it is an 'Immediate Report' under Israeli regulations concerning a 'Report on Financial Results for a Period of Six Months Ending June 30, 2021'. The key phrase is 'Attached hereto is a report on *Financial Results for a Period of Six Months Ending June 30, 2021*'. Since the document itself is short (1927 chars) and serves primarily to announce the availability of the attached financial report (which covers a six-month period), it fits the definition of a Report Publication Announcement (RPA) rather than the comprehensive Interim Report (IR) itself. The mention of 'Six Months Ending June 30, 2021' strongly suggests an interim report is attached. H1 2021
2021-08-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It references the issuance of unaudited interim condensed consolidated financial statements as of June 30, 2021, and an Operating and Financial Review and Prospects report. Form 6-K is used by foreign private issuers to report material information between annual reports. The document itself is a filing announcing the attached interim financial statements and review, not the full interim report itself. The document length is 2548 characters, which is relatively short and consistent with an announcement or filing rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes Form 6-K filings that announce reports rather than containing full financial data themselves.
2021-08-24 English
Final Prospectus-June 7, 2021
Investor Presentation Classification · 95% confidence The document is explicitly titled "PROSPECTUS" and discusses the offer for sale of American Depositary Shares (ADSs) and ordinary shares, detailing the securities being registered, the selling shareholders, the trading markets (Nasdaq, TASE), risk factors, and SEC/securities authority disclaimers. This content is characteristic of a registration statement filed with the SEC to offer securities to the public. Among the provided codes, 'POS' (Transaction in Own Shares) or 'CAP' (Capital/Financing Update) might seem related to share issuance, but the comprehensive nature, the explicit use of the term 'PROSPECTUS', and the context of offering securities for sale strongly indicate a registration document related to capital raising or share offering, which is best classified under a general offering/registration category. Since there is no specific code for a 'Prospectus' or 'Registration Statement', and this document details the terms of an offering of shares/ADSs, it aligns most closely with 'CAP' (Capital/Financing Update) or potentially 'SHA' (Share Issue/Capital Change) if focusing only on the shares being offered. However, a Prospectus is the primary document for a public offering. Given the options, and recognizing that a prospectus is the core document for a public offering of securities, 'CAP' (Capital/Financing Update) is the most appropriate fit for a document detailing the terms of a large-scale share offering, even if it's a resale by selling shareholders. If 'TAR' (Takeover/M&A) or 'SHA' were broader, they might fit, but 'CAP' covers financing activities. Since this is a formal SEC filing document detailing an offering, and it is not a periodic report (10-K, IR) or a short announcement (RPA), 'CAP' is selected as the best fit for a major financing/offering document.
2021-06-09 English
Final Prospectus-June 7, 2021
Report Publication Announcement Classification · 98% confidence The document is a regulatory filing notification from XTL BIOPHARMACEUTICALS LTD, reported via MAGNA to the Israel Securities Authority and the Tel Aviv Stock Exchange. The key indicator is the line: "Attached hereto is a report on *Final Prospectus* *ea142399-424b3_xtlbiopharmaEDGAR2bannerless_isa.pdf*". This structure—a short announcement stating that a specific report (in this case, a Final Prospectus, which is a type of offering document) is attached or published—fits the definition of a Report Publication Announcement (RPA) according to Rule 2 (The 'Menu vs Meal' Rule). A Final Prospectus relates to capital raising or offering, but since this document is merely announcing the publication of the prospectus rather than being the prospectus itself, RPA is the most appropriate classification.
2021-06-09 English
PROSPECTUS SUPPLEMENT
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to the offer for sale of American Depositary Shares (ADSs). It details the securities offered, the selling shareholders, use of proceeds, plan of distribution, risk factors, and other information typical of a capital raising document. It is not a financial report, earnings release, or management discussion. It is a detailed disclosure document for a securities offering, which fits the definition of a Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief summary. Therefore, the correct classification is Capital/Financing Update (CAP).
2021-06-09 English
Regulatory Filings 2021
Regulatory Filings
2021-06-08 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.